|
HLA-DQB1
|
0.700 |
Biomarker
|
disease |
BEFREE |
To replicate and/or extend these findings, we have tested HLA-DQB1, the previously identified 5 variants, and 10 other potential variants in a large European sample of narcolepsy with cataplexy subjects.
|
24381371 |
2014 |
|
HLA-DQB1
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The study confirmed the association of the HLA-DQB1*06:02 allele with narcolepsy and cataplexy susceptibility.
|
24571861 |
2014 |
|
HLA-DQB1
|
0.700 |
GeneticVariation
|
disease |
GWASCAT |
Genome wide analysis of narcolepsy in China implicates novel immune loci and reveals changes in association prior to versus after the 2009 H1N1 influenza pandemic.
|
24204295 |
2013 |
|
HLA-DQB1
|
0.700 |
Biomarker
|
disease |
BEFREE |
We found a strong HLA-DQB1(∗)06:02 association in narcolepsy+cataplexy subjects (odds ratio [OR], 321.4 [95% confidence interval {CI}, 70.7-1461.4]).
|
24157097 |
2013 |
|
HLA-DQB1
|
0.700 |
Biomarker
|
disease |
BEFREE |
This results were comparable with other authors, confirming the utility of using specific biomarkers (HLA-DQB1*0602 allele and Hypocretin-1 CSF level) in narcolepsy with cataplexy.
|
21049180 |
2010 |
|
HLA-DQB1
|
0.700 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy.
|
20711174 |
2010 |
|
HLA-DQB1
|
0.700 |
Biomarker
|
disease |
BEFREE |
Across populations, low CSF hcrt-1 and HLA-DQB1*0602-positivity characterized the majority of NC (80% to 100%, P = 0.53; 80% to 100%, P = 0.11) but a minority of NwC patients (11% to 29%, P = 0.75; 29% to 89%, P = 0.043).
|
20175400 |
2010 |
|
HLA-DQB1
|
0.700 |
SusceptibilityMutation
|
disease |
ORPHANET |
Association of narcolepsy-cataplexy with HLA-DRB1 and DQB1 in Mexican patients: a relationship between HLA and gender is suggested.
|
18706091 |
2008 |
|
HLA-DQB1
|
0.700 |
Biomarker
|
disease |
BEFREE |
Seventeen young adults with a sole diagnosis of HLA DQB1 0602 positive narcolepsy with cataplexy (25.1 +/- 4.6 years old) and 17 healthy comparison subjects (26.8 +/- 4.8 years old).
|
18363310 |
2008 |
|
HLA-DQB1
|
0.700 |
Biomarker
|
disease |
BEFREE |
About three quarters of the HLA DQB1*0602 positive patients with narcolepsy and cataplexy had low CSF hypocretin-1 values, and appear to form a distinct clinical entity.
|
17702265 |
2007 |
|
HLA-DQB1
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
HLA-DQB1 genotyping in a family with narcolepsy-cataplexy.
|
17658488 |
2007 |
|
HLA-DQB1
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Sporadic narcolepsy with cataplexy is a disabling disease that is strongly associated with the major histocompatibility class II allele HLA DQB1*0602 and is characterized by profound reduction in the cerebrospinal fluid (CSF) concentration of hypocretin 1 levels.
|
16401544 |
2005 |
|
HLA-DQB1
|
0.700 |
Biomarker
|
disease |
BEFREE |
These ELISA assay results do not support the hypothesis that HLA DQB1*0602-positive narcolepsy with cataplexy is associated with serum antibodies against preprohypocretin or its cleavage products.
|
16171287 |
2005 |
|
HLA-DQB1
|
0.700 |
Biomarker
|
disease |
BEFREE |
Biological markers of narcolepsy with cataplexy (classical narcolepsy) include sleep-onset REM periods (SOREM) on multiple sleep latency tests (MSLT), HLA-DQB1*0602 positivity, low levels of cerebrospinal fluid (CSF) hypocretin-1 (orexin A), increased body mass index (BMI), and high levels of CSF leptin.
|
14592354 |
2003 |